LEQVIO® works differently from other LDL-C-lowering therapies by preventing the production of PCSK9 in the liver.1–3,5
What makes it innovative?
Instead of blocking circulating PCSK9 like other LDL-C-lowering therapies, LEQVIO®, as an siRNA therapy, interferes with the RNA that codes for this protein, reducing its production in the first place.1–3,5
Watch the video below to learn more about the mechanism of action of LEQVIO®.
The potential benefits of LEQVIO® and its properties:
DNA, deoxyribonucleic acid; LDL-C, low-density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9; RNA, ribonucleic acid; RNAi, ribonucleic acid interference; siRNA, small interfering RNA.
- LEQVIO® Great Britain. Summary of Product Characteristics.
- LEQVIO® Northern Ireland. Summary of Product Characteristics.
- Stoekenbroek RM, et al. Future Cardiol 2018;14(6):433–442.
- Lamb YA. Drugs 2021;81(3):389–395.
- Klinovski M, et al. Inclisiran: a small interfering RNA molecule for treating hypercholesterolemia. Ottawa: CADTH; 2019. CADTH Issues in Emerging Health Technologies; Issue 180.
- Khvorova AN, Engl J Med 2017;376(1):4–7.
- Fitzgerald K, et al. N Engl J Med 2017;376(1):41–51.
- Nordestgaard BG, et al. Nat Rev Cardiol 2018;15(5):261–272.
LEQVIO® and the LEQVIO® logo are registered trademarks of Novartis AG. Licensed from Alnylam Pharmaceuticals, Inc.